LTZ Therapeutics is engaged in the development of innovative immunotherapies aimed at treating patients with cancer and other diseases that currently lack effective treatment options. The company employs reverse translational science and tumor biology, integrating these approaches with machine learning to advance its immunotherapy solutions. This strategy enables LTZ Therapeutics to create novel cancer treatments that address significant unmet clinical needs, ultimately striving to improve patient outcomes in the field of oncology.
Beino Bio is a China-based supplier of biopharmaceutical CDMO and cell culture media, providing process development and GMP production services for companies interested in introducing protein, cell therapy and gene therapy drugs to the Chinese and global markets.
Jisi Yingda is a small-molecule anti-cancer drug developer, in the field of small-molecule tumor immune drugs and tumor drug development.
CytoLynx Therapeutics is a R&D and commercial platform leveraging Cytovia’s unique technologies and product pipeline.
Adlai Nortye Biopharma Co., Ltd. is a biopharmaceutical company based in Hangzhou, China, focused on the research and development of innovative treatments for cancer and metabolic diseases. Founded in 2004 and formerly known as Sinopep Pharmaceutical Inc., the company has shifted its emphasis to oncology and immuno-oncology. Adlai Nortye is committed to improving patient outcomes through the discovery and commercialization of differentiated medicines. With a solid foundation in peptide and protein drug development, the company has broadened its scope to include small molecules and therapeutic antibodies. It holds 23 granted patents and has published 7 PCT applications. Through strategic collaborations with global partners, Adlai Nortye has established a diverse pipeline of programs ranging from early pre-clinical stages to those ready for phase 3 clinical trials.
Provider and developer of new drugs designed for cardiovascular diseases, metabolic disorders and cancer. The company focuses on G-protein coupled receptors (GPCRs) therapeutic antibody and Bibody development and has established a robust pipeline for diabetes, obesity, NASH, PAH and heart failure, providing patients with better efficacy and lower side effects in treatment.
Hinova Pharmaceuticals Inc. is a drug discovery and development company based in Chengdu, China, with additional branches in Hong Kong, Texas, and Australia. Established in 2013, the company specializes in the research and manufacturing of innovative medicines to address unmet medical needs, particularly in oncology and metabolic diseases. Utilizing advanced technology platforms such as deuterium and PROTAC, Hinova develops both Best-in-class and First-in-class drugs. Its product pipeline includes the HC-1119 androgen receptor antagonist and HC-1102 androgen receptor inhibitors, which target advanced prostate cancer and breast cancer. The company's commitment lies in providing safe, effective, and affordable treatments while retaining global rights and interests in its drug portfolio.
Adlai Nortye Biopharma Co., Ltd. is a biopharmaceutical company based in Hangzhou, China, focused on the research and development of innovative treatments for cancer and metabolic diseases. Founded in 2004 and formerly known as Sinopep Pharmaceutical Inc., the company has shifted its emphasis to oncology and immuno-oncology. Adlai Nortye is committed to improving patient outcomes through the discovery and commercialization of differentiated medicines. With a solid foundation in peptide and protein drug development, the company has broadened its scope to include small molecules and therapeutic antibodies. It holds 23 granted patents and has published 7 PCT applications. Through strategic collaborations with global partners, Adlai Nortye has established a diverse pipeline of programs ranging from early pre-clinical stages to those ready for phase 3 clinical trials.
Asieris Pharmaceuticals Co. Ltd. is a Chinese biotechnology company established in 2010 and headquartered in Taizhou, China. The company specializes in the research and development of pharmaceutical products aimed at treating tumors and addressing multidrug-resistant infections. Asieris focuses on innovative therapies within the oncology sector and is dedicated to combating the challenges posed by drug-resistant pathogens.
CANbridge Pharma is a biopharmaceutical company focused on the development and commercialization of healthcare products in China and North Asia, particularly for oncology and rare diseases. Established in 2012 and headquartered in Beijing, with additional offices in Shanghai, Cambridge, Taipei, and Hong Kong, the company partners with Western biopharmaceutical firms to bring clinical-stage pharmaceutical, medical device, and diagnostic products to the region. CANbridge specializes in therapies for serious medical conditions that are either unavailable or inadequately addressed in North Asia. Its key product, CAN008, is a glycosylated CD95-Fc fusion protein aimed at treating glioblastoma multiforme, while the company also has a diverse pipeline of biologics and small molecules targeting conditions such as Hunter Syndrome, hemophilia A, and various rare metabolic disorders. Through licensing and exclusive commercialization agreements, CANbridge seeks to enhance healthcare solutions for underserved patient populations in the region.
EOC Group is a biopharmaceutical company based in Shanghai, China, founded in 2015. The company specializes in developing, manufacturing, and commercializing innovative oncology products, utilizing a licensing model to enhance its product pipeline. EOC partners with global biopharmaceutical firms to integrate their molecules into its local manufacturing and regulatory frameworks. The company currently has a pipeline of seven novel products, four of which have received Class I innovative drug approvals and are undergoing clinical studies in China. EOC operates an 8,000 square meter cGMP manufacturing facility in Taizhou, China Medical City, and maintains offices in major cities, including Shanghai, Beijing, Hong Kong, and Los Angeles. With a team experienced in pharmaceutical research and development, EOC aims to position itself as a leader in oncology innovation within China.
EOC Group is a biopharmaceutical company based in Shanghai, China, founded in 2015. The company specializes in developing, manufacturing, and commercializing innovative oncology products, utilizing a licensing model to enhance its product pipeline. EOC partners with global biopharmaceutical firms to integrate their molecules into its local manufacturing and regulatory frameworks. The company currently has a pipeline of seven novel products, four of which have received Class I innovative drug approvals and are undergoing clinical studies in China. EOC operates an 8,000 square meter cGMP manufacturing facility in Taizhou, China Medical City, and maintains offices in major cities, including Shanghai, Beijing, Hong Kong, and Los Angeles. With a team experienced in pharmaceutical research and development, EOC aims to position itself as a leader in oncology innovation within China.
Provider of medical translation service based in China. The company provides the translation service of research, registration, marketing, training, management and other documents of drugs, medical devices, biological products, animal protection, and vaccines in Chinese, English, Japanese, German, French, and other languages.
CMAB BioPharm is a Biopharmaceutical Service Firm.
Suqiao Bio is a flexible, comprehensive biopharmaceutical custom development and production (CDMO) service company. Strictly in compliance with the quality standards of domestic and international pharmaceutical production management regulations, Suqiao Bio is committed to providing Chinese and global customers with a one-stop shop for preclinical and clinical drug Phase I, Phase II, and Phase III biopharmaceutical products from DNA sequences to commercial production. solution.
Collietech is a Chinese electronic common technical document (eCTD) software and service provider, focusing on information technology in life science field.
Med Circle (Beijing) Information Technology Co., Ltd. specializes in internet services in the medical industry. It is based in China.
Provider of medical translation service based in China. The company provides the translation service of research, registration, marketing, training, management and other documents of drugs, medical devices, biological products, animal protection, and vaccines in Chinese, English, Japanese, German, French, and other languages.
NovaSignal is a medical technology company commercializing a robotic cerebral ultrasound system. Its Robotic System combines non-invasive ultrasound, robotics, and artificial intelligence to assess real-time cerebral blood flow. Through the use of cloud computing and data analytics, NovaSignal supports physicians in their clinical decision making to help improve patient outcomes. It was founded in 2013 and is headquartered in Los Angeles, California.
DreamCIS, Inc. is a contract research organization based in Seoul, South Korea, founded in 2000. The company specializes in providing a wide range of clinical research services, including clinical development, biostatistics, data management, pharmacovigilance, medical writing, and quality assurance. It caters to pharmaceutical companies, medical device firms, and health-related organizations, focusing on drug and medical device clinical trials, post-marketing research, and human body testing for functional foods. Additionally, DreamCIS offers regulatory consulting and workforce training to address the specific needs of its clients. The company is committed to maintaining high standards of quality control and ethical practices while supporting its clients throughout the clinical research process across various therapeutic areas, including oncology, cardiovascular, endocrinology, and rare diseases.
Frontage Holdings Corporation is a contract research organization that offers a range of research, analytical, and development services primarily to pharmaceutical, biotechnology, and agrochemical companies. Founded in 2018 and headquartered in Exton, Pennsylvania, Frontage supports drug discovery and development through services such as drug metabolism, pharmacokinetics, safety and toxicology, and bioanalytical testing. Additionally, the company provides comprehensive support for clinical studies, including early-stage clinical trials and biometrics, as well as product development and bioequivalence studies. Frontage operates in various regions, including the United States, Canada, China, Europe, India, Japan, Korea, Israel, and Australia, with a significant portion of its revenue generated from North America. As a subsidiary of Hong Kong Tigermed Co., Limited, Frontage plays a vital role in advancing research and development efforts for biopharmaceutical organizations, facilitating the submission of drug applications and enhancing the efficiency of the drug development process.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.